NASDAQ: BCLI
Brainstorm Cell Therapeutics Inc Stock Ownership - Who owns Brainstorm Cell Therapeutics?

Insider buying vs selling

Have Brainstorm Cell Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Chaim LebovitsPresident CEO2024-10-011,836$3.43
$6.29kBuy
Chaim LebovitsPresident CEO2024-09-3022,000$0.23
$5.02kBuy
Ibrahim B. DagherChief Medical Officer2024-07-1963,000$0.35
$22.05kSell

1 of 1

BCLI insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when BCLI insiders and whales buy or sell their stock.

BCLI Shareholders

What type of owners hold Brainstorm Cell Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Accbt Corp365.38%29,006,924$34.52MInsider
Sankesh Abbhi27.41%2,175,853$2.59MInsider
Armistice Capital LLC8.70%690,666$821.89kInstitution
Ibrahim B. Dagher6.37%505,742$601.83kInsider
Jonathan C. Javitt5.79%460,000$547.40kInsider
Chaim Lebovits4.21%334,349$397.88kInsider
Michael D. Greenfield3.78%300,000$357.00kInsider
Chen Schor3.11%247,116$294.07kInsider
Ralph Dr Kern2.81%223,310$265.74kInsider
Caldwell Sutter Capital Inc1.98%157,009$186.84kInstitution

1 of 3

BCLI vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
BCLI2.90%97.10%Net Selling
CYCN11.60%88.40%Net Selling
CANF0.00%0.00%
CBIO30.02%69.98%Net Selling
IBO2.89%17.46%Net SellingNet Selling

Brainstorm Cell Therapeutics Stock Ownership FAQ

Who owns Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics (NASDAQ: BCLI) is owned by 12.89% institutional shareholders, 430.90% Brainstorm Cell Therapeutics insiders, and 0.00% retail investors. Accbt Corp is the largest individual Brainstorm Cell Therapeutics shareholder, owning 29.01M shares representing 365.38% of the company. Accbt Corp's Brainstorm Cell Therapeutics shares are currently valued at $35.68M.

If you're new to stock investing, here's how to buy Brainstorm Cell Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.